Dr. Olanow is the Henry P. and Georgette Goldschmidt Professor and Chairman Emeritus of the Department of Neurology, and Professor in the Department of Neuroscience at the Mount Sinai School of Medicine in New York City. He serves on the Board of Directors of the National Space Biomedical Research Institute, is a member of the executive committee of the Michael J. Fox Foundation Scientific Advisory Board, is the past Chairman of the Scientific Advisory Board of the Bachmann-Strauss Foundation and has served on numerous additional medical and scientific advisory boards. He has served on several editorial boards, and is presently Co-Editor-in-Chief of the journal Movement Disorders. His clinical and basic science research efforts are directed toward defining more effective therapies for Parkinson’s disease and other neurodegenerative disorders. Dr. Olanow has authored more than 350 publications, and was ranked #1 in the United States in citations for Parkinson’s disease during the past decade, and during the past quarter century. He has lectured on movement disorders at Universities and Conferences throughout the world. Dr. Olanow received his medical degree from the University of Toronto, performed his neurology training at the New York Neurological Institute at Columbia Presbyterian Medical Center at Columbia University.
Dr. Rascol has been Professor of Clinical Pharmacology in Toulouse University Hospital since 1993. He specialized in Neurology in Toulouse and obtained his PhD in Neurosciences in Paris. Dr. Rascol has headed the Toulouse Clinical Research Centre since 1994. As a neuro-pharmacologist, Dr Rascol’s main fields of interest are Parkinson’s disease and movement disorders, drug development for Parkinson’s disease and functional neuroimaging. Dr. Rascol has been actively involved in the development of several marketed anti-Parkinsonian medications (Ropinirole, Rasagiline). He is on the board of the Evidence-Based Medicine MDS Task Force.
Dr. Kieburtz is the Director of the Clinical and Translational Science Institute and the Robert J Joynt Professor of Neurology, Professor of Environmental Medicine, and of Community and Preventive Medicine, and Senior Associate Dean for Clinical Research at the University of Rochester. Dr. Kieburtz is the Principal Investigator for the NIH Exploratory Trials in PD (NET-PD) program, and other NIH supported multi-center clinical trials. He has led over 35 NIH, industry and foundation supported multi-site projects in neurodegenerative diseases. He has served as the Chair of the Executive Committee of the Parkinson Study Group and as a Scientific Advisor to the Alzheimer Disease Cooperative Study Group. He has served on the International Executive Committee of the Movement Disorders Society, the Executive Council of the American Neurological Association, and the Chair of the Peripheral and Central Nervous System Advisory Committee of the FDA. Dr. Kieburtz obtained his BA in Neuroscience from Amherst College. He completed his MD and MPH degrees at the University of Rochester, as well as his residency and a fellowship in Experimental Therapeutics.
Peter A LeWitt
Dr. LeWitt is a Professor of Neurology at Wayne State University School of Medicine and directs the Parkinson’s Disease and Movement Disorders Program at Henry Ford Hospital in West Bloomfield , Michigan , USA . Dr. LeWitt is a specialist in treatment and research for Parkinson’s disease and other movement disorders. In addition to clinical experience, he has directed laboratory research investigating neurochemical mechanisms and diagnostic markers in Parkinson’s and Alzheimer’s diseases. He has been active in numerous clinical studies involving Parkinson’s disease and other movement disorders and neurodegenerative conditions. Dr. LeWitt has authored more than 300 publications on clinical and basic neuroscience. He has been a steering committee member and clinical investigator for the Parkinson Study Group and other clinical trial research consortia. He serves on the editorial board of the Journal of Neural Transmission, Translation Neurodegeneration, and Journal of Parkinson’s Disease, and is editor-in-chief of Clinical Neuropharmacology.
Dr. Giladi is a Professor of Neurology, Chairman at the Department of Neurology in the Tel Aviv Medical Center, Director of the Department pf Neurology Sackler School of Medicine and Chairman of the Medical Advisory Board to the Israeli Parkinson Association. Dr. Giladi specialized in Movement Disorders with Prof. Stanley Fahn at Columbia University, New York, USA. He was a Visiting Professor at University of Oxford, Oxford Centre for Cognitive Neuroscience, England and at Radboud University School of Medicine Nijmegen, Netherlands. He is the Director of the Parkinson Centre and the Movement Disorders Unit, recognized as an International Centre of Excellence of the National Parkinson Foundation at the Neurology department of Tel Aviv Medical Center, Israel.
Dr. Nutt is a Professor of Neurology and Physiology & Pharmacology, Co-Founder and Emeritus Director of the OHSU Parkinson Center of Oregon and Movement Disorders Program and Emeritus Director of the Portland VAMC Parkinson’s Disease Research, Education and Clinical Center. Dr. Nutt has gained international recognition for his innovative research in movement disorders and is widely recognized for his work on the pharmacokinetics of levodopa which has provided significant clinical and scientific insight on this important therapy for PD. His background in pharmacology has made him a world leader in testing many novel therapeutics for Parkinson’s disease as well as new neuroprotective and neurorestorative therapies. He has also become a world leader and international expert in understanding the gait and balance problems of PD and ways to better manage these problems.
Dr. Poewe is Professor of Neurology and Director of the Department of Neurology at Innsbruck Medical University in Innsbruck, Austria. He held a Residency in Clinical Neurology and Psychiatry at the University of Innsbruck, Austria, from 1977 to 1984. Then, Dr. Poewe was a British Council Research Fellow at University College and Middlesex Hospital Medical School, London. For three years (1986-1989), he was a Senior Lecturer in the Department of Neurology at the University of Innsbruck, Austria. From 1990 through 1994 he served as Professor of Neurology and Acting Director of the Department of Neurology at the Virchow Hospital of the Free University of Berlin. Dr. Poewe’s main research interests are in the field of movement disorders with particular emphasis on the clinical pharmacology of Parkinson’s disease and dystonia. He has authored and co-authored more than 550 original articles and reviews in the field of movement disorders. He served as President of the International Movement Disorder Society from 2000 through 2002, as President of the Austrian Society of Neurology from 2002 to 2004 and is the past President of the Austrian Parkinson’s Disease Society as well as the past Chair of the Movement Disorders Society/European Section.